Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-03-29
2011-03-29
Joike, Michele K (Department: 1636)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S069600
Reexamination Certificate
active
07915395
ABSTRACT:
The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.
REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5883223 (1999-03-01), Gray
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6623940 (2003-09-01), Ledbetter et al.
patent: 6641809 (2003-11-01), Linsley et al.
patent: 6685941 (2004-02-01), Thompson et al.
patent: 6719972 (2004-04-01), Gribben et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6830937 (2004-12-01), Linsley et al.
patent: 2001/0053361 (2001-12-01), Thompson et al.
patent: 2002/0031510 (2002-03-01), Larsen et al.
patent: 2002/0039577 (2002-04-01), Townsend et al.
patent: 2002/0115214 (2002-08-01), June et al.
patent: 2002/0182211 (2002-12-01), Peach et al.
patent: 2003/0007968 (2003-01-01), Larsen et al.
patent: 2003/0022836 (2003-01-01), Larsen et al.
patent: 2003/0083246 (2003-05-01), Cohen et al.
patent: 2003/0219863 (2003-11-01), Peach et al.
patent: 2004/0014171 (2004-01-01), Peach et al.
patent: 2004/0022787 (2004-02-01), Cohen et al.
patent: 0 439 095 (1991-07-01), None
patent: 0 506 124 (1992-09-01), None
patent: WO 88/01649 (1988-03-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO90/05541 (1990-05-01), None
patent: WO 92/00092 (1992-01-01), None
patent: WO 93/00431 (1993-01-01), None
patent: WO93/19767 (1993-10-01), None
patent: WO94/28912 (1994-12-01), None
patent: WO95/33770 (1995-12-01), None
patent: WO97/28267 (1997-08-01), None
patent: WO2004/058800 (2004-07-01), None
patent: WO2004/058944 (2004-07-01), None
patent: WO2005/016266 (2005-02-01), None
Hanson et al. Electron microscopic and hydrodynamic studies of protein immunoglobulin G soluble complexes. J. of Immunology 132(3): 1386-1396, 1984.
Eisenberg, D. et al., “The Design, Synthesis, and Crystallization of an Alpha-Helical Peptide”, Proteins: Structure, Function, and Genetics vol. 1, pp. 16-22 (1986).
Perez, P. et al., “Specific targeting of human peripheral blood t cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies”, J. of Experimental Medicine, vol. 163, pp. 166-178 (1986).
Taylor, J. et al., “Opioid receptor selectivity of peptide models of β-endorphin”, Int. J. Peptide Protein Res., vol. 34, pp. 75-80 (1989).
Hayden, M. et al., “Single-chain mono-and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system”, Therapeutic Immunology, vol. 1, pp. 3-15 (1994).
Anderson et al., “Crosslinking of T3 (CD3) With T4 (CD4) Enhances the Proliferation of Resting T Lymphocytes,”J. Immunol., 1987, 139:678-682. (Exhibit 1).
Capon et al., “Designing CD4 Immunoadhesions for AIDS Therapy,”Nature, 1989, 337:525-531. (Exhibit 2).
Chappel et al., “ Identification of the Fc Receptor Class I Binding Site in Human IgG Through the Use of Recombinant IgG/IgG2 Hybrid and Point-Mutated Antibodies,”Proc. Natl. Acad. Sci. USA, 1991, 88:9036-9040. (Exhibit 3).
Davis et al., “Single Chain Antibody (SCA) encoding Genes: One Step Construction and Expression in Eukaryotic Cells,”Biotechnology, 9:165-169. (Exhibit 4).
Emmrich et al., “Selective Stimulation of Human T Lymphocyte Subsets by Heteroconjugates of Antibodies to the T-cell Receptor and to Subset-specific Differentiation Antigens,”Eur. J. Immunol, 1988, 18:645-648. (Exhibit 5).
Ford et al., “Fusion Tails for the Recovery and Purification of Recombinant Proteins,”Protein Expression and Purification, 1991, 2:95-107. (Exhibit 6).
Fouser et al., “High Level Expression of a Chimerc Antigen-Ganglioside GD2 Antibody: Genomic Kappa Sequences Improve Expression in COS and CHO Cells,”Biotechnology, 1992, 10:1121-1127. (Exhibit 7).
Hieter et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments,”Cell, 1980, 22:197-207. (Exhibit 8).
Jung et al., “Induction of Cytotoxicity in Resting Human T Lymphocytes bound to Tumor Cells by Antibody Heteroconjugates,”Proc. Natl. Acad. Sci. USA, 1987, 84:4611-4615. (Exhibit 9).
Ledbetter et al., “Signal Transduction Through CD4 Proximity to the CD3/T Cell Receptor,”Eur. J. Immunol., 1988, 18:525-532. (Exhibit 10).
Ledbetter et al., “Enhanced Transmemebrane Signalling Activity of Monoclonal Antibody Heteroconjugates Suggest Molecular Interactions Between Receptor on the T Cell Surface,”Mol. Imunol., 1989, 26:137-145. (Exhibit 11).
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimultes T Cell Proliferation and Interleukin 2 mRNA Accumulation,”J. Exp. Med., 1991, 173:721-730. (Exhibit 12).
Liu et al., “Heteroantibody Duplexes Target Cells for Lysis by cytotoxic T Lymphocytes,”Proc. Natl. Acad. Sci. USA, 1985, 82:8648-8652. (Exhibit 13).
Liu et al., “Chimeric Mouse-Human IgG1 Antibody that can Mediate Lysis for Cancer Cells,”Proc. Natl. Acad. Sci. USA., 1987, 84:3439-3443. (Exhibit 14).
Lund et al., “ Human Fc RI and Fc RII Interact with Distinct but Overlapping Sites on Human IgG,”Journal of Immunology, 1991, 147:2657-2662. (Exhibit 15).
Mayforth et al., “Current Concepts: Designer and Catalytic Antibodies,”New Eng. J. Med., 1990, 323:173-178. (Exhibit 16).
Morrison et al., “In Vitro Antibodies: Strategies for Production and Application,”Ann. Rev. Immunol., 1992, 10:239-266. (Exhibit 17).
Neuberger et al., “Recombinant Antibodies Possesing novel Effector Functions,”Nature, 1984, 312:604-608. (Exhibit 18).
Orlandi et al. “Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction,”Proc. Nat. Acad. Sci. USA, 1989, 86:3833-3837. (Exhibit 19).
Perez et al., “Specific Targeting of Cytotoxic T Cells by Anti-T3 Linked to Anti-Target Cell Antibody,”Nature, 1985, 316:354-356. (Exhibit 20).
Perez et al., “Specific Targeting of Cytotoxic T Cells by Anti-T3 Linked to Anti-Target Cell Antibody,”Nature, 1985, 316:354-356. (Exhibit 21).
Shopes, B. “A Genetically Engineered Human IgG Mutant Cytolytic Activity,”Journal of Immunology, 1992, 148(9):2918-2922. (Exhibit 22).
Staerz et al., “Hybrid Hybridoma Producing a Bispecific Monoclonal Antibody that can Focus Effector T-Cell Activity,”Proc. Natl. Acad. Sci. USA, 1986, 83:1453-1457. (Exhibit 23).
Traunecker et al., “Bispecific Single Chain Molecules(Janusins) Target Cytotoxi Lymphocytes on HIV Infected Cells,”EMBO, 1991, 10:3655-3659. (Exhibit 24).
Emmrich et al., “Synergism in the Activation of Human CD8 T Cells by Cross-Linking the T-Cell Receptor Complex with the CD8 Differentation
Bajorath Jurgen
Fell H. Perry
Gilliland Lisa K.
Hayden Martha S.
Ledbetter Jeffrey A.
Bristol--Myers Squibb Company
Joike Michele K
Parlet Nickki L.
LandOfFree
Expression vectors encoding bispecific fusion proteins and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression vectors encoding bispecific fusion proteins and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression vectors encoding bispecific fusion proteins and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2674228